Phase 1 โ Early testing in a small group of people (usually 20โ80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(2 sites)
Japan
Nagoya University Hospital, Nagoya, Aich The University of Tokyo Hospital, Tokyo